Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
机构:[1]Fu Wai Hosp, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China;[2]Yale Univ, Sch Med, New Haven, CT USA;[3]Shanghai Jiao Tong Univ, Sch Med, Affiliated Ruijin Hosp, Shanghai 200030, Peoples R China;[4]Capital Med Univ, Affilaited Anzhen Hosp, Beijing, Peoples R China;首都医科大学附属安贞医院[5]Daqing Oil Field Gen Hosp, Daqing, Peoples R China;[6]Nanjing Med Univ, Nanjing Hosp 1, Nanjing, Jiangsu, Peoples R China;江苏省人民医院[7]Shenyang Northern Hosp, Shenyang, Peoples R China;[8]Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Xian 710049, Peoples R China;[9]Peking Univ, Hosp 1, Beijing 100871, Peoples R China;[10]Natl Ctr Cardiovasc Dis China, Beijing, Peoples R China;[11]Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY USA
Gao Run-Lin,Xu Bo,Lansky Alexandra,et al.Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials[J].JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY.2013,62(18):B59-B59.doi:10.1016/j.jacc.2013.08.915.
APA:
Gao, Run-Lin,Xu, Bo,Lansky, Alexandra,Yang, Yuejin,Zhang, Ruiyan...&Leon, Martin.(2013).Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,62,(18)
MLA:
Gao, Run-Lin,et al."Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials".JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 62..18(2013):B59-B59